Key result
Oral L-arginine improves acetylcholine-mediated coronary blood flow reserve to ~149% vs. placebo.
Why the study?
Coronary endothelial dysfunction involves imbalance of vasodilating and vasoconstricting factors and coronary vasoconstriction to acetylcholine, and the effect of long-term L-arginine supplementation on this dysfunction was unknown.
Does oral L-arginine improve endothelium-dependent coronary blood flow reserve in patients with nonobstructive coronary artery disease?
RCT (n=26)
Double-blind
randomized
Does oral L-arginine improve endothelium-dependent coronary blood flow reserve in patients with nonobstructive coronary artery disease?
Long-term oral L-arginine supplementation for 6 months improves coronary small-vessel endothelial function and symptoms in patients with nonobstructive coronary artery disease.
Answers are grounded in this paper and cite their sources.
Supports L-arginine for endothelial dysfunction in nonobstructive CAD; extends prior data to long-term randomized oral use.
BACKGROUND: Coronary endothelial dysfunction is characterized by an imbalance between endothelium-derived vasodilating and vasoconstricting factors and coronary vasoconstriction in response to the endothelium-dependent vasodilator acetylcholine. Thus, the present double-blind, randomized study was designed to test the hypothesis that long-term, 6-month supplementation of L-arginine, the precursor of the endothelium-derived vasodilator NO, reverses coronary endothelial dysfunction to acetylcholine in humans with nonobstructive coronary artery disease. METHODS AND RESULTS: Twenty-six patients without significant coronary artery disease on coronary angiography and intravascular ultrasound were blindly randomized to either oral L-arginine or placebo, 3 g TID. Endothelium-dependent coronary blood flow reserve to acetylcholine (10(-6) to 10(-4) mol/L) was assessed at baseline and after 6 months of therapy. There was no difference between the two study groups in clinical characteristics or in the coronary blood flow in the response to acetylcholine at baseline. After 6 months, the coronary blood flow in response to acetylcholine in the subjects who were taking L-arginine increased compared with the placebo group (149 +/- 20% versus 6 +/- 9%, P < 0.05). This was associated with a decrease in plasma endothelin concentrations and an improvement in patients' symptoms scores in the L-arginine treatment group compared with the placebo group. CONCLUSIONS: Long-term oral L-arginine supplementation for 6 months in humans improves coronary small-vessel endothelial function in association with a significant improvement in symptoms and a decrease in plasma endothelin concentrations. This study proposes a role for L-arginine as a therapeutic option for patients with coronary endothelial dysfunction and nonobstructive coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Lerman et al. (1998) conducted an RCT in nonobstructive coronary artery disease (n=26). oral L-arginine vs. placebo was evaluated on Endothelium-dependent coronary blood flow reserve to acetylcholine (p=< 0.05). Long-term oral L-arginine supplementation increased coronary blood flow in response to acetylcholine compared with placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: